Advertisement

Bio-Rad Laboratories, Inc. C1000 Articles

Image: Bio-Rad Launches a Range of Anti-idiotypic Antibodies Targeting Pembrolizumab and Nivolumab

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-idiotypic antibodies targeting the immune checkpoint inhibitor drugs:...

Image: Bio-Rad Expedites Disease Biomarker Discovery and Drug Development with the Launch of Bio-Plex Pro Human Cytokine Screening Panel

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the Bio-Plex Pro Human Cytokine Screening Panel, the first validated high-performance multiplex assay on the market. The panel can identify and quantify 48 different...

Image: Bio-Rad Introduces an Assay Website That Allows Researchers to Identify or Design Their Own Droplet Digital™ PCR Assays

Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb) today announced the launch of an assay website that allows droplet digital PCR (ddPCR™) users to locate existing assays or design new ones for mutation detection and copy number determination...

Image: Bio-Rad Launches ddPCR™ CHO and E. coli Kits for Direct Quantification of Residual Host Cell DNA

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of two residual DNA quantification (RDQ) kits to simplify the quantification of host-cell DNA (HCD) in process development, quality control, and biomanufacturing processes...

Image: Bio-Rad’s New Software Makes Purifying Proteins with NGC™ Chromatography Systems Even Easier

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today released ChromLab™ Software Version 4.0. When used with the NGC Chromatography System, the software version continues the ChromLab legacy of enabling researchers to purify their proteins...